Six points of application will be defined in the quadriceps and two points of application in the gastrocnemius. The parameters adopted for the irradiation will be: 30 Joules per application point, wavelength of 660 and 850 nm and output power of 200 mW. Each point will be radiated for 30 seconds.

This group will receive no intervention. This group will be evaluated before the intervention, after four and eight weeks of follow up.

Low-Level Light Therapy

Renal Insufficiency, Chronic

Renal Dialysis

Clinical Trial

For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.

Low Level Laser Therapy

Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure

Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure on Hemodialysis: Randomized Clinical Trial

Functional capacity will be assessed by the Six-Minute Walk Test

DNA damage will be assessed by the alkaline comet assay

Muscle strength of lower limbs will be assessed by dynamometry

Muscle architecture of quadriceps will be assessed by ultrasonography

Muscle pain will be assessed by analogic visual scale

Fatigue of lower limbs will be assessed by Borg's subjective effort perception scale Fatigue of lower limbs will be assessed by Borg's effort perception scale

Oxidative stress will be assessed by measurement of oxidative and antioxidant markers

Inflammatory profile will be assessed by measurement of interleukins and markers of muscle damage

Quality of life will be assessed by Kidney Disease and Quality-of-Life Short-Form questionnaire

Quality of life will be assessed by EQ-5D

Rodrigo Della Méa Plentz

Principal Investigator

Federal University of Health Science of Porto Alegre

CHF patients were identified from inpatients as well as patients attending outpatient clinics and from the general practice in the community. Diagnosis of CHF was based on the European Society of Cardiology guidelines for CHF. All patients with stable CHF were included in the study. Inpatients with CHF who were hospitalized were also included, except patients with acutely decompensated CHF requiring intravenous therapy. CHF patients with a previous diagnosis of diabetes mellitus were excluded from the study.

A group of healthy subjects were also studied. They were recruited from the community and were clinically healthy based on history, physical examination, and blood laboratory results and were not taking any medication.

Congestive Heart Failure

Heart Failure

University of Dundee

Insulin Resistance : Heart Failure

Insulin Resistance: A New Target in Heart Failure

Fasting insulin resistance index was assessed in a cohort of 129 consecutive CHF patients testing and peripheral endothelial function testing by reactive hyperemia peripheral arterial tonometry (RH-PAT).

sulfuric acid/necrose

Effects of Low Level Laser Therapy on Functional Capacity and DNA Damage of Patients With Chronic Kidney Failure

Insulin Resistance : Heart Failure

O mais completo banco de dados de ervas medicinais apoiado pela ciência